Bessemer Group
STLN

Bessemer Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bessemer Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Hold
1,024
– – ﹤0.01% 2283
2025
Q4 		$4K Buy
+1,024
New +$3.8K ﹤0.01% 2303

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's STLN Position: Q1 2026 in Review

Bessemer Group held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q1 2026 at 1,024 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Bessemer Group first reported a position in STLN in Q4 2025 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Bessemer Group held 1,024 shares of Starling Oncology Institute, Inc. Common Stock worth $4K as of Q1 2026.
  • Bessemer Group left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2283 holding.
  • Bessemer Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.